急性后循環(huán)腦梗死靜脈溶栓聯(lián)合人尿激肽原酶治療后血清VEGF、MMP-9變化的臨床研究
發(fā)布時(shí)間：2018-12-23 09:10
【摘要】：目的探討急性后循環(huán)腦梗死靜脈溶栓后聯(lián)合人尿激肽原酶治療的安全性及有效性,觀察治療后血清VEGF、MMP-9水平的變化。方法采用隨機(jī)平行對(duì)照研究,以急性后循環(huán)腦梗死患者為研究對(duì)象,以rt-PA靜脈溶栓聯(lián)合人尿激肽原酶為聯(lián)合治療組,單純靜脈溶栓治療為對(duì)照組,采用NIHSS、mRS量表評(píng)價(jià)臨床療效;以酶聯(lián)免疫吸附法檢測(cè)不同治療時(shí)間VEGF、MMP-9的水平。結(jié)果聯(lián)合治療組及對(duì)照組NIHSS治療前后均有統(tǒng)計(jì)學(xué)差異(P0.05)。聯(lián)合治療組與對(duì)照組治療后90 d的BI評(píng)分及治療后30 d和90 d的mRS評(píng)分均有統(tǒng)計(jì)學(xué)差異(P0.05)。聯(lián)合治療組較對(duì)照組在治療后不同時(shí)間,VEGF均有不同程度升高;MMP-9隨治療時(shí)間延長(zhǎng)呈下降趨勢(shì)。結(jié)論 rt-PA靜脈溶栓聯(lián)合人尿激肽原酶的方法在臨床上是安全的,并能顯著改善神經(jīng)功能的缺損。其可能機(jī)制除早期開(kāi)通血管外,還可能通過(guò)調(diào)節(jié)VEGF、MMP-9的水平,促進(jìn)側(cè)支循環(huán)的建立。
[Abstract]:Objective to investigate the safety and efficacy of intravenous thrombolytic therapy combined with human urinary kallikrein in patients with acute posterior circulation cerebral infarction (ARCI), and to observe the changes of serum VEGF,MMP-9 levels after treatment. Methods A randomized parallel controlled study was conducted in patients with acute posterior circulation cerebral infarction. Rt-PA intravenous thrombolytic therapy combined with human urinary kallikrein was used as the combined treatment group and intravenous thrombolytic therapy was used as the control group. NIHSS, was used as the control group. MRS scale was used to evaluate the clinical efficacy. Enzyme linked immunosorbent assay (Elisa) was used to detect the level of VEGF,MMP-9 at different treatment time. Results there were significant differences between the combined treatment group and the control group before and after NIHSS treatment (P0.05). The BI scores of the combined treatment group and the control group were significantly different from those of the control group at 90 days after treatment and 30 and 90 days after treatment (P0.05). Compared with the control group, the VEGF of the combined treatment group increased in different degrees, and the MMP-9 decreased with the prolongation of the treatment time. Conclusion rt-PA intravenous thrombolysis combined with human urinary kallikrein is safe in clinical practice and can significantly improve nerve function defect. In addition to the early opening of blood vessels, the mechanism may also promote the establishment of collateral circulation by regulating the level of VEGF,MMP-9.
【作者單位】： 深圳市羅湖醫(yī)院集團(tuán)湖貝社區(qū)健康服務(wù)中心;北京大學(xué)深圳醫(yī)院神經(jīng)內(nèi)科;
【基金】：深圳市衛(wèi)計(jì)委科研項(xiàng)目(201302074) 深圳市科創(chuàng)委科研項(xiàng)目(JYCJ20140415162338844)
【分類號(hào)】：R743.33
[Abstract]:Objective to investigate the safety and efficacy of intravenous thrombolytic therapy combined with human urinary kallikrein in patients with acute posterior circulation cerebral infarction (ARCI), and to observe the changes of serum VEGF,MMP-9 levels after treatment. Methods A randomized parallel controlled study was conducted in patients with acute posterior circulation cerebral infarction. Rt-PA intravenous thrombolytic therapy combined with human urinary kallikrein was used as the combined treatment group and intravenous thrombolytic therapy was used as the control group. NIHSS, was used as the control group. MRS scale was used to evaluate the clinical efficacy. Enzyme linked immunosorbent assay (Elisa) was used to detect the level of VEGF,MMP-9 at different treatment time. Results there were significant differences between the combined treatment group and the control group before and after NIHSS treatment (P0.05). The BI scores of the combined treatment group and the control group were significantly different from those of the control group at 90 days after treatment and 30 and 90 days after treatment (P0.05). Compared with the control group, the VEGF of the combined treatment group increased in different degrees, and the MMP-9 decreased with the prolongation of the treatment time. Conclusion rt-PA intravenous thrombolysis combined with human urinary kallikrein is safe in clinical practice and can significantly improve nerve function defect. In addition to the early opening of blood vessels, the mechanism may also promote the establishment of collateral circulation by regulating the level of VEGF,MMP-9.
【作者單位】： 深圳市羅湖醫(yī)院集團(tuán)湖貝社區(qū)健康服務(wù)中心;北京大學(xué)深圳醫(yī)院神經(jīng)內(nèi)科;
【基金】：深圳市衛(wèi)計(jì)委科研項(xiàng)目(201302074) 深圳市科創(chuàng)委科研項(xiàng)目(JYCJ20140415162338844)
【分類號(hào)】：R743.33
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 孔祥敏;;后循環(huán)腦梗死156例臨床與預(yù)后探究[J];當(dāng)代醫(yī)學(xué);2013年30期
2 潘志信;后循環(huán)腦梗死早期誤診32例分析[J];中國(guó)誤診學(xué)雜志;2001年07期
3 李菁晶;鞠奕;王春雪;王擁軍;;老年后循環(huán)腦梗死患者89例臨床觀察[J];中國(guó)神經(jīng)免疫學(xué)和神經(jīng)病學(xué)雜志;2008年03期
4 盧桂蘭;冀瑞俊;;后循環(huán)腦梗死溶栓治療成敗的分析[J];中風(fēng)與神經(jīng)疾病雜志;2009年03期
5 王力軍;;后循環(huán)腦梗死68例臨床分析[J];臨床醫(yī)學(xué);2009年12期
6 李R，
本文編號(hào)：2389755
本文鏈接：http://sikaile.net/yixuelunwen/shenjingyixue/2389755.html
最近更新
教材專著
